Loading provider…
Loading provider…
Hematology & Oncology Physician in Columbus, OH
NPI: 1174753537Primary Practice Location
OHIO STATE UNIVERSITY STATE HEALTH SYSTEM
1670 Upham Dr, Columbus, OH
Primary Employer
OSU Internal Medicine
wexnermedical.osu.edu
HQ Phone
Get MD David's Phone Numberphone_androidMobile
Get MD David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License

American Board of Internal Medicine
Medical Oncology
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 60 | 196 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 29 | 40 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 21 | 21 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 11 | 36 |
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.
Authors: George Blumenschein, Elliot Norry, Philip Mccarthy, Dejka Araujo, Anthony Olszanski, Partow Kebriaei, Armin Ghobadi, Paula Fracasso, Anne Grand'Maison, Amanda Cashen, Mihaela Druta
Publication Date: 2021-12-09
Emerging Trends in Immunotherapy for Adult Sarcomas.
Authors: Claire Verschraegen, Joal Beane, Luxi Chen
Journal: Oncologist
Lead Sponsor: Moleculin Biotech, Inc.
Intervention / Treatment: DRUG: Liposomal Annamycin (L-Annamycin)
Lead Sponsor: Adaptimmune
Intervention / Treatment: DRUG: Cyclophosphamide, DRUG: Fludarabine, DRUG: Letetresgene autoleucel (lete-cel, GSK3377794)
Lead Sponsor: Adaptimmune
Intervention / Treatment: GENETIC: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, RADIATION: Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation